However, recent large-scale, clinical trials have shown that treatment with SGLT2 inhibitors have improved renal outcome not only in patients with diabetic kidney disease (DKD), but also in patients with chronic kidney disease (CKD) without diabetes (3–5). This evidence concerns the gene SLC5A2 and diabetes mellitus.